秦皇岛康体检机构(潮州六可以体检么) (今日更新中)

The Electric Daisy Carnival in Las Vegas has been postponed yet again and is joining a growing list of companies canceling or pushing back in-person events amid the pandemic.EDC Las Vegas 2020 was originally scheduled to take place at the Las Vegas Motor Speedway in May of this year. Due to the coronavirus pandemic, the event was pushed back to October.On Sunday, however, Insomniac CEO and Founder Pasquale Rotella announced new dates for the event, officially postponing it to next year.The new dates are May 21-23, 2021.RELATED: Events in Las Vegas pull plug amid coronavirus pandemicAccording to the EDC website, all tickets will be honored for the new dates. If you are unable to attend the rescheduled dates, customers are asked to fill out the festival verification here. In a post to Instagram, Rotella wrote: 827

The COVID-19 pandemic has hit people of color particularly hard, and one new study says that may be because of racial disparities in treating high blood pressure.According to the American Heart Association's Scientific Sessions, one-third of disparities in treatment may be the result of racial inequalities in prescribing or increasing the dosage of new medications used in treating high blood pressure.The study found that blood pressure control rates are lower in Black patients compared to other racial groups. Black patients also had more missed opportunities for treatment and missed more clinic appointments."A doctor might think a patient is less likely less able to afford medications, and because of that, they choose to not prescribe a certain medication," said Dr. Valy Fontil, an assistant professor of medicine at UCSF and one of the researchers involved in the study. "Or, they might know this person doesn't have transportation to the clinic, and so sometimes it might even be well-intentioned."Fontil says more standardized treatment protocols would help eliminate the disparities and prevent missed opportunities to get someone the medication they need."Sometimes people present, and the main thing that they're there for is not for the blood pressure," he said. "So, the clinician just sort of kind of might ignore the blood pressure. So automating these sort of standardized treatments would tell the clinician that they — even if the patient's not here for blood pressure — you have to address it in some way."Previous studies have also shown Black patients have more apprehension about why someone is giving them more medication. Fontil says one solution is having the patient be part of the treatment decision making.Fontil adds that the increasing number of virtual visits for blood pressure issues could make the racial disparities even worse. 1876

The case of the world's most litigious selfie has come to a close.The People for the Ethical Treatment of Animals (PETA) and photographer David Slater have reached a settlement in a dispute over who owns the rights to a selfie of a monkey.The photograph was taken in 2011 by a 7-year-old crested macaque named Naruto. 325

The fog hangs heavy over Great Bay along the New Hampshire seacoast on a raw as Josh Carloni and his wife, Jessica, emerge through the mist on their fishing boat.They are the owners of Rising Tide Oyster Company, a family-owned business that typically sells thousands of oysters a year to restaurants across New England. But when the novel coronavirus hit back in March, their sales disappeared overnight as restaurants were forced to closed.“Every time you turn on the news, there’s just more bad news out there,” said Carloni. “Our business is down maybe 20 percent.”The Carlonis and oyster fisherman across the country were finding themselves in similar positions. They suddenly had thousands of perfectly healthy oysters that needed to be harvested, but there was no place for them to go.“Oyster farmers had been growing these oysters for three years, and suddenly, they didn’t have a market at all. The pandemic hit oyster farmers across the country hard,” explained Alix Laferriere, who serves as the Marine and Coastal Director for the Nature Conservancy of New Hampshire.Laferriere and her team thought there was little they could do to help struggling oyster farmers until a few months ago when an anonymous donor gifted a million donation.With that sudden infusion of cash, Laferriere and her team got to work. With help from the Pew Charitable Trust, they developed the Supporting Oyster Aquaculture and Restoration (SOAR) initiative to buy back five million oysters that needed to be harvested. The program is being deployed in seven states: Maine, New Hampshire, Massachusetts, New York, New Jersey, Maryland and Washington state.But it’s not just helping fisherman’s bottom line, it’s also helping estuaries and reefs at the bottom of the ocean.Turns out oysters don't just taste good; they can do good for the environment. That grant bought back 10,000 of Josh Carloni's oysters. And he isn't just throwing them into the ocean. Laferriere and her team have strategically told him where they should be deployed across the Great Bay Estuary along New Hampshire's coast. Eventually, the oysters will latch on to reefs below and help restore the damage done by decades of overharvesting, pollution and disease.“It’s this win-win opportunity where we get to put oysters back in the bay and help our local oyster farmers,” explained Briana Group, who also works with the Nature Conservancy of New Hampshire.One adult oyster can filter up to 30 gallons of water a day, and when they’re filtering that water, they’re removing nitrogen from the ecosystem.While the program is giving fisherman an infusion of cash, it’s also giving reefs and estuaries across the country an infusion of clean water, courtesy of a 3-inch mollusk.“There’s nothing bad about this situation; it’s only good,” Laferriere said as she looked out over the ocean.For fisherman like Josh Carloni, the program means he gets to keep his business afloat for another year, while at the same time, giving back to the environment. And it’s all because of COVID-19.“It makes us feel really good about doing something good for the environment,” he said. 3134

The Food and Drug Administration released updated safety standards Tuesday for makers of COVID-19 vaccines despite efforts by the White House to block them, clearing the way for requirements that are widely expected to prevent the introduction of a vaccine before Election Day.In the new guidelines posted on its website, the FDA said vaccine makers should follow trial participants for at least two months to rule out any major side effects before seeking emergency approval. That standard had been a sticking point between the FDA and White House officials, who said it could unreasonably delay the availability of COVID-19 vaccines.President Donald Trump has repeatedly insisted a vaccine could be authorized before Nov. 3, even though top government scientists working on the effort have said that timeline is very unlikely. On Monday Trump said vaccines are coming “momentarily,” in a video recorded after he returned to the White House.Former FDA officials have warned that public perception that a vaccine was being rushed out for political reasons could derail efforts to vaccinate millions of Americans.A senior administration official confirmed Monday that the White House had blocked FDA’s plans to formally publish the safety guidelines based on the two-month data requirement, arguing there was “no clinical or medical reason” for it.But on Tuesday, the FDA posted the guidance on its website, making clear that regulators plan to impose the safety standards for any vaccine seeking an expedited path to market.FDA Commissioner Stephen Hahn said in a statement that he hoped the guidelines would help “the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy.”The requirements are aimed at companies seeking rapid approval through the FDA’s emergency authorization pathway. That accelerated process, reserved for health emergencies, allows medical products onto the market based on a lower bar than traditional FDA approval. But FDA has made clear only vaccines that are shown to be safe and effective will be authorized for coronavirus.Former FDA acting commissioner Dr. Stephen Ostroff said the requirements seem reasonable given the agency is in largely “uncharted territory” in terms of considering emergency use of a vaccine. The agency has only previously cleared one vaccine through the method — a decades-old shot that was authorized to prevent anthrax poisoning in 2005.“There really is no margin for error here,” Ostroff said. “Even when you’re talking about limited use of a vaccine there has to be some level of assurance that there isn’t a risk here that would far outweigh the benefit.”Dr. Peter Marks, the head of FDA’s vaccine division, said Tuesday that the two-month follow-up requirement was chosen to be “something reasonably aggressive, but not too conservative — right in the middle.” He spoke at a symposium organized by Johns Hopkins University.Initial doses of vaccines for emergency use would likely be reserved for medical workers and people with health conditions that make them particularly vulnerable to coronavirus. Full FDA approval for the general population will require significantly more data and is not expected until mid-2021.The White House attempt to block the guidance followed a string of instances in which the Trump administration has undercut its own medical experts working to combat the pandemic. FDA’s Hahn has been attempting to shore up public confidence in the vaccine review process for weeks, vowing that career scientists, not politicians, will decide if the shots are safe and effective.Pfizer CEO Albert Bourla has stoked excitement by saying that he expects data on whether the company’s candidate works to be ready in late October. But a number of variables would still have to align for the company to submit, and the FDA to review and greenlight, a vaccine application before Nov. 3. Pfizer’s competitors Moderna, AstraZeneca and Johnson & Johnson are working on longer research timelines.Vaccine development typically takes years, but the U.S. government has invested billions in efforts to accelerate the process and help multiple drugmakers prepare multiple candidates. All the doses will be purchased by the federal government for use vaccinating the U.S. population.Beyond exposing the rift between the White House and FDA, the delay in releasing the guidelines may have had limited practical effect.FDA scientists have been discussing the guidelines publicly for weeks and have made clear that the recommendations have already been shared with each of the vaccine developers.Former FDA Commissioner Scott Gottlieb said Tuesday that drugmakers depend on the FDA’s science-based endorsement to vouch for the safety and effectiveness of their products.“I can’t imagine a circumstance where a sponsor would challenge or seek to undermine the FDA’s role here,” Gottlieb said at the COVID-19 symposium. “This is precisely the moment when we need an objective, neutral arbiter.”Last week, Gottlieb and six other former FDA commissioners blasted the Trump administration for “undermining the credibility” of the agency in a op-ed calling for the release of the then-stalled vaccine guidelines.“Scientists should make decisions based on data, unfettered by political pressure or the intrusions of ideology or vested interests,” the officials wrote.___AP Medical Writer Lauran Neergaard contributed to this report.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5644

来源：资阳报